Browse the corpus

Immunotherapy is a pivotal intervention in managing a spectrum of immunological disorders, from immunodeficiencies to malignancies. This activity discusses the diverse modalities of immunotherapy, their mechanisms of action, potential adverse events, and crucial considerations such as dosing and monitoring. Participants will explore the conditions amenable to immunotherapeutic interventions to better comprehend immunotherapy's role in enhancing the quality of life and longevity of afflicted individuals. Attendees will gain additional insights into immunotherapeutic agents by discussing their pharmacodynamics, pharmacokinetics, and pertinent interactions. By fostering a comprehensive understanding of immunotherapeutic principles, this program empowers healthcare teams to deliver personalized, efficacious care to patients navigating immunological challenges, thereby advancing the frontier of modern medicine. Objectives: Identify different categories of immunotherapy. Determine indicated conditions for each type of immunotherapy. Identify some of the contraindications of various forms of immunotherapy. Select interprofessional team strategies for improving care coordination and communication to advance immunotherapy, improve outcomes, and minimize adverse events. Access free multiple choice questions on this topic.

The use of IVIG has expanded significantly over the past 3 decades. Providing care to patients with immune deficiencies is most effective with an interprofessional team that includes clinicians (MDs, DOs, NPs, PAs), specialists, hematology nurses, and pharmacists. While IVIG is effective, patients need to understand that the therapy is not benign and is associated with adverse effects. Close monitoring of patients is necessary because of allergies, anaphylaxis, and graft-versus-host reactions. Given the potential for adverse events with immunotherapy, the entire team must be vigilant for these reactions. The pharmacist must have close involvement with nursing and the clinician staff, with all members of the interprofessional team informed and communicating regarding the adverse event profile. This is so immunotherapy has the best chance to help the patient with minimal chance for adverse effects.